Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 9, 2010, Pages 963-971

  Kim, Ayako ^a   Serada, Satoshi ^a   Enomoto, Takayuki ^b   Naka, Tetsuji ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Annexin A4; Chemoresistance; Clear cell carcinoma of the ovary; Molecular targeted therapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 4; PACLITAXEL; SMALL INTERFERING RNA;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; CLEAR CELL CARCINOMA; DRUG SENSITIVITY; DRUG TARGETING; FEMALE; HUMAN; OVARY CARCINOMA; OVARY CLEAR CELL CARCINOMA; PROGNOSIS; REVIEW;

ADENOCARCINOMA, CLEAR CELL; ANNEXIN A4; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS;

EID: 77955434582     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2010.511180     Document Type: Review

References (83)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
2. Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007;109:221-227 (Pubitemid 46106236)
3. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004;3:355-366 (Pubitemid 38702089)
4. Colombo N, Van Gorp T, Parma G, et al. Ovarian cancer. Crit Rev Oncol Hematol 2006;60:159-179 (Pubitemid 44636248)
5. Gultekin M, Diribas K, Buru E, et al. Interval debulking in epithelial ovarian carcinomas: the past, present and the future. Eur J Gynaecol Oncol 2008;29:242-245 (Pubitemid 351744485)
6. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000;88:2584-2589 (Pubitemid 30331967)
7. Aure JC, Hoeg K, Kolstad P. Clinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases. Obstet Gynecol 1971;37:1-9
8. Kennedy AW, Biscotti CV, Hart WR, Webster KD. Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989;32:342-349
9. Itamochi HK, J. Incidence of ovarian cancer in Japan. Obstet Gynecol (Tokyo) 2005;5:545-549
10. Schiller W. Mesonephroma ovarii. Am J Cancer 1939;35:1-21
11. Serov SF, Scully RE, Sobin LH. Histological typing of ovarian tumours. (International Histological Classification No.9). World Health Organization 1973. p. 17-54
12. Yoonessi M, Weldon D, Satchidand SK, Crickard K. Clear cell ovarian adenocarcinoma. J Surg Oncol 1984;27:289-297 (Pubitemid 15179702)
13. Itamochi H, Kigawa J, Sultana H, et al. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Jpn J Cancer Res 2002;93:723-728 (Pubitemid 34846281)
14. Behbakht K, Randall TC, Benjamin I, et al. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol 1998;70:255-258 (Pubitemid 28430939)
15. Mandai M, Yamaguchi K, Matsumura N, et al. Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management. Int J Clin Oncol 2009;14:383-391
16. Kobayashi H. Ovarian cancer in endometriosis: epidemiology, natural history, and clinical diagnosis. Int J Clin Oncol 2009;14:378-382
17. Stern RC, Dash R, Bentley RC, et al. Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol 2001;20:133-139 (Pubitemid 32239204)
18. Modesitt SC, Tortolero-Luna G, Robinson JB, et al. Ovarian and extraovarian endometriosis-associated cancer. Obstet Gynecol 2002;100:788-795 (Pubitemid 35300039)
19. Jenison EL, Montag AG, Griffiths CT, et al. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol 1989;32:65-71
20. Ogawa S, Kaku T, Amada S, et al. Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and mmunohistochemical study. Gynecol Oncol 2000;77:298-304 (Pubitemid 30317153)
21. Yamaguchi K, Mandai M, Toyokuni S, et al. Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress. Clin Cancer Res 2008;14:32-40 (Pubitemid 351377975)
22. Enomoto T, Kuragaki C, Yamasaki M, et al. Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? Proc Am Soc Clin Oncol 2003;22(A1797):447
23. Ho CM, Huang YJ, Chen TC, et al. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol Oncol 2004;94:197-203
24. Goff BA, Sainz de la Cuesta R, Muntz HG, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996;60:412-417 (Pubitemid 26077628)
25. Mizuno M, Kikkawa F, Shibata K, et al. Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary. J Surg Oncol 2006;94:138-143 (Pubitemid 44267195)
26. Winter WE III, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:3621-3627 (Pubitemid 47372600)
27. Winter WE III, Maxwell GL, Tian C, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2008;26:83-89
28. Chan JK, Teoh D, Hu JM, et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 2008;109:370-376
29. Pectasides D, Fountzilas G, Aravantinos G, et al. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 2006;102:285-291 (Pubitemid 44041640)
30. Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 2008;99:653-658 (Pubitemid 351448066)
31. Shimizu M, Nikaido T, Toki T, et al. Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas. Cancer 1999;85:669-677 (Pubitemid 29075288)
32. Oishi T, Itamochi H, Kigawa J, et al. Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary. Int J Gynecol Cancer 2007;17:1040-1046 (Pubitemid 47414828)
33. Kim HR, Lin HM, Biliran H, Raz A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res 1999;59:4148-4154 (Pubitemid 29393591)
34. Lin HM, Moon BK, Yu F, Kim HR. Galectin-3 mediates genistein-induced G2/M arrest and inhibits apoptosis. Carcinogenesis 2000;21:1941-1945
35. Inohara H, Raz A. Functional evidence that cell surface galectin-3 mediates homotypic cell adhesion. Cancer Res 1995;55:3267-3271
36. Matarrese P, Fusco O, Tinari N, et al. Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int J Cancer 2000;85:545-554 (Pubitemid 30075135)
37. Inohara H, Akahani S, Raz A. Galectin-3 stimulates cell proliferation. Exp Cell Res 1998;245:294-302 (Pubitemid 28565771)
38. Yang RY, Liu FT. Galectins in cell growth and apoptosis. Cell Mol Life Sci 2003;60:267-276
39. Yoshida S, Furukawa N, Haruta S, et al. Theoretical model of treatment strategies for clear cell carcinoma of the ovary: focus on perspectives. Cancer Treat Rev 2009;35:608-615
40. Tsuchiya A, Sakamoto M, Yasuda J, et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 2003;163:2503-2512 (Pubitemid 37466491)
41. Marquez RT, Baggerly KA, Patterson AP, et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 2005;11:6116-6126
42. Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005;11:6422-6430 (Pubitemid 41338978)
43. Kim A, Enomoto T, Serada S, et al. Enhanced expression of annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin. Int J Cancer 2009;125:2316-2322
44. Morita A, Miyagi E, Yasumitsu H, et al. Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma. Proteomics 2006;6:5880-5890 (Pubitemid 44764024)
45. Miao Y, Cai B, Liu L, et al. Annexin IV is differentially expressed in clear cell carcinoma of the ovary. Int J Gynecol Cancer 2009;19:1545-1549
46. Kobayashi H, Yamada Y, Kanayama S, et al. The role of hepatocyte nuclear factor-1beta in the pathogenesis of clear cell carcinoma of the ovary. Int J Gynecol Cancer 2009;19:471-479
47. Yamaguchi K, Mandai M, Oura T, et al. Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 2010;29:1741-1752
48. Kaetzel MA, Hazarika P, Dedman JR. Differential tissue expression of three 35-kDa annexin calcium-dependent phospholipid-binding proteins. J Biol Chem 1989;264:14463-14470 (Pubitemid 19214282)
49. Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev 2002;82:331-371 (Pubitemid 34654456)
50. Mussunoor S, Murray GI. The role of annexins in tumour development and progression. J Pathol 2008;216:131-140
51. Gerke V, Creutz CE, Moss SE. Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 2005;6:449-461 (Pubitemid 40780557)
52. Rescher U, Gerke V. Annexins-unique membrane binding proteins with diverse functions. J Cell Sci 2004;117:2631-2639 (Pubitemid 38997247)
53. Liemann S, Huber R. Three-dimensional structure of annexins. Cell Mol Life Sci 1997;53:516-521 (Pubitemid 27374492)
54. Rand JH. The annexinopathies: a new category of diseases. Biochim Biophys Acta 2000;1498:169-173
55. Hayes MJ, Moss SE. Annexins and disease. Biochem Biophys Res Commun 2004;322:1166-1170
56. Alfonso P, Canamero M, Fernandez-Carbonie F, et al. Proteome analysis of membrane fractions in colorectal carcinomas by using 2D-DIGE saturation labeling. J Proteome Res 2008;7:4247-4255
57. Duncan R, Carpenter B, Main LC, et al. Characterisation and protein expression profiling of annexins in colorectal cancer. Br J Cancer 2008;98:426-433 (Pubitemid 351161239)
58. Edwards HC, Crumpton MJ. Ca2+-dependent phospholipid and arachidonic acid binding by the placental annexins VI and IV. Eur J Biochem 1991;198:121-129
59. Zanotti G, Malpeli G, Gliubich F, et al. Structure of the trigonal crystal form of bovine annexin IV. Biochem J 1998;329(Pt 1):101-106 (Pubitemid 28022296)
60. Newman RH, Leonard K, Crumpton MJ. 2D crystal forms of annexin IV on lipid monolayers. FEBS Lett 1991;279:21-24
61. Kaetzel MA, Mo YD, Mealy TR, et al. Phosphorylation mutants elucidate the mechanism of annexin IV-mediated membrane aggregation. Biochemistry 2001;40:4192-4199
62. Oling F, Santos JS, Govorukhina N, et al. Structure of membrane-bound annexin A5 trimers: a hybrid cryo-EM-X-ray crystallography study. J Mol Biol 2000;304:561-573 (Pubitemid 32006190)
63. Pigault C, Follenius-Wund A, Schmutz M, et al. Formation of two-dimensional arrays of annexin V on phosphatidylserine-containing liposomes. J Mol Biol 1994;236:199-208 (Pubitemid 24148958)
64. Voges D, Berendes R, Burger A, et al. Three-dimensional structure of membrane-bound annexin V. A correlative electron microscopy-X-ray crystallography study. J Mol Biol 1994;238:199-213 (Pubitemid 124001980)
65. Reviakine II, Bergsma-Schutter W, Brisson A. Growth of protein 2-D crystals on supported planar lipid bilayers imaged in situ by AFM. J Struct Biol 1998;121:356-361 (Pubitemid 28364479)
66. Kaetzel MA, Chan HC, Dubinsky WP, et al. A role for annexin IV in epithelial cell function. Inhibition of calcium-activated chloride conductance. J Biol Chem 1994;269:5297-5302 (Pubitemid 24239525)
67. Chan HC, Kaetzel MA, Gotter AL, et al. Annexin IV inhibits calmodulin-dependent protein kinase II-activated chloride conductance. A novel mechanism for ion channel regulation. J Biol Chem 1994;269:32464-32468
68. Xie W, Kaetzel MA, Bruzik KS, et al. Inositol 3,4,5,6-tetrakisphosphate inhibits the calmodulin-dependent protein kinase II-activated chloride conductance in T84 colonic epithelial cells. J Biol Chem 1996;271:14092-14097 (Pubitemid 26190303)
69. Sohma H, Ohkawa H, Hashimoto E, et al. Alteration of annexin IV expression in alcoholics. Alcohol Clin Exp Res 2001;25:55S-58S (Pubitemid 32553352)
70. Ohkawa H, Sohma H, Sakai R, et al. Ethanol-induced augmentation of annexin IV in cultured cells and the enhancement of cytotoxicity by overexpression of annexin IV by ethanol. Biochim Biophys Acta 2002;1588:217-225 (Pubitemid 35223465)
71. Zimmermann U, Balabanov S, Giebel J, et al. Increased expression and altered location of annexin IV in renal clear cell carcinoma: a possible role in tumour dissemination. Cancer Lett 2004;209:111-118 (Pubitemid 38625750)
72. Sitek B, Luttges J, Marcus K, et al. Application of fluorescence difference gel electrophoresis saturation labelling for the analysis of microdissected precursor lesions of pancreatic ductal adenocarcinoma. Proteomics 2005;5:2665-2679 (Pubitemid 40966494)
73. Xin W, Rhodes DR, Ingold C, et al. Dysregulation of the annexin family protein family is associated with prostate cancer progression. Am J Pathol 2003;162:255-261 (Pubitemid 36042007)
74. Han EK, Tahir SK, Cherian SP, et al. Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. Br J Cancer 2000;83:83-88 (Pubitemid 30352721)
75. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431-436 (Pubitemid 44050137)
76. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009;8:33-40
77. Sohma H, Ohkawa H, Sakai R, et al. Augmentation of ethanol-induced cell damage and activation of nuclear factor-kappaB by annexin IV in cultured cells. Alcohol Clin Exp Res 2003;27:64S-67S (Pubitemid 36999203)
78. Jeon YJ, Kim DH, Jung H, et al. Annexin A4 interacts with the NF-kappaB p50 subunit and modulates NF-kappaB transcriptional activity in a Ca2+-dependent manner. Cell Mol Life Sci 2010;67:2271-2281
79. Draeger A, Wray S, Babiychuk EB. Domain architecture of the smooth-muscle plasma membrane: regulation by annexins. Biochem J 2005;387:309-314 (Pubitemid 40571216)
80. Monastyrskaya K, Babiychuk EB, Draeger A. The annexins: spatial and temporal coordination of signaling events during cellular stress. Cell Mol Life Sci 2009;66:2623-2642
81. Kidd JF, Pilkington MF, Schell MJ, et al. Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore. J Biol Chem 2002;277:6504-6510
82. Yan X, Yin J, Yao H, et al. Increased expression of annexin A3 is a mechanism of platinum resistance in ovarian cancer. Cancer Res 2010;70:1616-1624
83. Scully RE. Recent progress in ovarian cancer. Hum Pathol 1970;1:73-98